Kerrie Brady, president and chief executive officer of OcuTerra Therapeutics, shares progress in their Phase 2 DR:EAM Diabetic Retinopathy study, with promising results expected in Q1 2024 for their OTT166 eye drop treatment.
Kerrie Brady, president and chief executive officer of OcuTerra Therapeutics, sat down with the Eye Care Network to share clinical updates at this year's American Academy of Ophthalmology meeting.
Editor's note - This transcript has been edited for clarity.
Hi, I'm Kerrie Brady, the president and chief executive officer of OcuTerra Therapeutics. We're delighted to be here at AAO 2023 to catch up on all the latest of what's happening in our industry. We're particularly excited to be here so that we can share news of developments at OcuTerra.
Most importantly, in the middle of this year, we announced full enrollment in our Phase 2 DR:EAM Diabetic Retinopathy Early Active Management study with our OTT166, which is a novel, selective integrin inhibitor, which has been designed to be able to be delivered as an eye drop.
So, now with full enrollment and the Phase 2 DR:EAM study, we're on schedule to have our topline results in the first quarter of next year.